Peripheral Neuropathy Trial, Recruiting (NCT05101304)

Peripheral Neuropathy Trial, Recruiting NCT05101304 Sponsor: Saving Lives Matters Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT05101304 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be an adult (18 years of age or older)
Adults who are under legal protection, such as guardianship or curatorship, may also be eligible
You may be eligible if you have been referred to a participating centre because doctors suspect you may have amyloidosis (a condition where abnormal proteins build up in the body's organs)
You may be eligible if you are already being treated at a participating centre and have a confirmed diagnosis of amyloidosis
Deceased patients who were previously followed at a participating centre with a confirmed diagnosis of amyloidosis may be included in the retrospective part of the study (confirm with trial site)
Eligible participants must sign the appropriate patient information and consent form for the relevant part of the study

Who may not be able to join:

Anyone who has clearly stated that they do not wish to take part in the study would not be included

Please note:

Taking part in another clinical study at the same time does not prevent you from joining this trial
Participants will not receive any payment for taking part in this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thibaud Pr Damy, Henri Mondor University Hospital

Phone: +33650029257

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05101304

Sponsor: Saving Lives Matters

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: +33650029257

More information: https://clinicaltrials.gov/study/NCT05101304

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be an adult (18 years of age or older)
Adults who are under legal protection, such as guardianship or curatorship, may also be eligible
You may be eligible if you have been referred to a participating centre because doctors suspect you may have amyloidosis (a condition where abnormal proteins build up in the body's organs)
You may be eligible if you are already being treated at a participating centre and have a confirmed diagnosis of amyloidosis
Deceased patients who were previously followed at a participating centre with a confirmed diagnosis of amyloidosis may be included in the retrospective part of the study (confirm with trial site)
Eligible participants must sign the appropriate patient information and consent form for the relevant part of the study

Who may not be able to join:

Anyone who has clearly stated that they do not wish to take part in the study would not be included

Please note:

Taking part in another clinical study at the same time does not prevent you from joining this trial
Participants will not receive any payment for taking part in this study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Saving Lives Matters

Registry

ClinicalTrials.gov

Start date

29 June 2021

Est. completion

30 June 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

The clinical, biological and imaging characteristics of patients with cardiac amyloidosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov